Profile
| Metric | Value |
|---|---|
| Full Name | argenx SE |
| Ticker | NASDAQ: ARGX |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | Netherlands |
| IPO | |
| Indexes | Not included |
| Website | argenx.com |
| Employees | 1,599 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $803.74 | |
| Price, 1D Change | +0.36% | |
| Market Cap | $49B | |
| - | ||
| PE Ratio | 103.57 | |
| Beta | 0.42 | |
| Revenue | $2B | |
| Revenue, 1Y Change | +78.01% | |
| EPS | $12.76 | |
| EPS, 1Y Change | +346.83% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | $12.76 | |
| EPS Estimate | $14.88 | |
| EPS Est. Change | +16.66% | |
| Revenue | $2.19B | |
| Revenue Estimate | $3.60B | |
| Revenue Est. Change | +64.63% | |
| Current Price | $803.74 | |
| Price Target | - | $1,001.64 |
| Price Tgt. Change | - | +24.62% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$4.84 | -$5.17 | -6.80% | |
| $2.32 | $12.76 | +449.82% | |
| $14.88 | N/A | +16.66% | |
| $25.45 | N/A | +99.45% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $1.23B | $1.23B | +0.17% | |
| $2.09B | $2.19B | +4.69% | |
| $3.60B | N/A | +64.63% | |
| $4.98B | N/A | +127.91% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +24.54% | |
| Price, 3Y | +113.87% | |
| Market Cap, 1Y | +26.20% | |
| Market Cap, 3Y | +137.70% | |
| Revenue, 1Y | +78.01% | |
| Revenue, 3Y | +340.36% | |
| EPS, 1Y | +346.83% | |
| EPS, 3Y | +259.86% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $803.74 | |
| SMA 200 | $697.02 | |
| SMA 200 vs Price | -13.28% | |
| SMA 50 | $869.38 | |
| SMA 50 vs Price | +8.17% | |
| Beta | 0.42 | |
| ATR | $19.11 | |
| 14-Day RSI | 26.05 | |
| 10-Day Volatility | 24.66% | |
| 1-Year Volatility | 32.32% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $2.19B | |
| EPS | $12.76 | |
| Gross Profit | $1.96B | |
| Gross Margin | 89.20% | |
| Operating Profit | -$63.85M | |
| Operating Margin | -2.92% | |
| Net Income | $831.57M | |
| Net Margin | 38.03% | |
| EBITDA | -$46.35M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.01 | |
| Current Ratio | 7.29 | |
| Quick Ratio | 6.68 | |
| Interest Coverage | - | |
| - | ||
| Altman Z-Score | 42.94 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | 103.57 | |
| PS Ratio | 13.73 | |
| PB Ratio | - | |
| EV/EBITDA | - | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $5.50B | |
| Cash & Equivalents | $1.50B | |
| Total Assets | $6.20B | |
| Current Assets | $4.88B | |
| Total Liabilities | $704.24M | |
| Current Liabilities | $669.92M | |
| Total Debt | $39.05M | |
| Short Term Debt | $6.53M | |
| Accounts Payable | $649.99M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $1.35B | |
| Operating Expenses | $2.01B | |
| Cost Of Goods Sold | $236.22M | |
| SG&A | $1.05B | |
| D&A | $17.50M | |
| Interest Expense | $0.00 | |
| Income Tax | -$792.56M |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | $28.85M | |
| CFI | -$827.78M | |
| CFF | $279.26M | |
| Capex | $68.18M | |
| Free Cash Flow | -$39.33M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Baird | → | |
| RBC Capital | → | |
| Wells Fargo | → | |
| Wells Fargo | → | |
| Stifel | → | |
| JP Morgan | → | |
| Morgan Stanley | → | |
| Wolfe Research | → | |
| Citigroup | → | |
| Wedbush | → |
Analyst sentiment
Institutional ownership
Screeners with ARGX
Data Sources & References
- ARGX Official Website argenx.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1697862/000169786225000024/0001697862-25-000024-index.htm
- ARGX Profile on Yahoo Finance finance.yahoo.com/quote/ARGX
- ARGX Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/argx
FAQ
What is the ticker symbol for argenx SE?
The ticker symbol for argenx SE is NASDAQ:ARGX
Does argenx SE pay dividends?
No, argenx SE does not pay dividends
What sector is argenx SE in?
argenx SE is in the Healthcare sector
What industry is argenx SE in?
argenx SE is in the Biotechnology industry
What country is argenx SE based in?
argenx SE is headquartered in Netherlands
When did argenx SE go public?
argenx SE initial public offering (IPO) was on May 18, 2017
Is argenx SE in the S&P 500?
No, argenx SE is not included in the S&P 500 index
Is argenx SE in the NASDAQ 100?
No, argenx SE is not included in the NASDAQ 100 index
Is argenx SE in the Dow Jones?
No, argenx SE is not included in the Dow Jones index
When was argenx SE last earnings report?
argenx SE's most recent earnings report was on October 30, 2025
When does argenx SE report earnings?
The next expected earnings date for argenx SE is February 26, 2026